CSCI (Cosciens Biopharma) Net Income From Continuing Operations : $-15.31 Mil (TTM As of Dec. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cosciens Biopharma's net income from continuing operations for the three months ended in Dec. 2024 was $-6.73 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was $-15.31 Mil.

Cosciens Biopharma Net Income From Continuing Operations Historical Data

The historical data trend for Cosciens Biopharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma Net Income From Continuing Operations Chart

Cosciens Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

1.46

2.64

3.45

-3.49

-15.31

Cosciens Biopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-1.56	-1.40	-1.42	-5.76	-6.73

Cosciens Biopharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.31 Mil.

Cosciens Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (NAS:CSCI) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

ET8:Germany CSCI:Canada

Address

c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.